1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone profile

The compound you've described, **1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone**, is a complex organic molecule with a unique structure.

Here's a breakdown of its significance:

* **Structure:** The compound is a substituted quinoline derivative with a fused cyclopentane ring and a benzodioxole moiety. This specific arrangement of atoms and functional groups is key to its potential biological activity.
* **Potential for Research:** Due to its structure and the presence of a bromine atom and a carbonyl group, this compound likely possesses characteristics that make it interesting for research in various fields. Here's why:

* **Pharmacological Activity:** The presence of the quinoline scaffold and the benzodioxole group are known to be associated with a variety of pharmacological activities. These could include:
* **Anti-inflammatory Properties:** Quinoline derivatives have been shown to exhibit anti-inflammatory effects.
* **Anti-cancer Properties:** Certain quinoline derivatives have anticancer activity.
* **Antimicrobial Properties:** Some quinolines show antibacterial or antifungal properties.
* **Other Potential Applications:** Depending on the specific structural modifications, the compound could have activity in other areas such as neurological disorders, cardiovascular diseases, or even as a dye or pigment.

* **Importance for Research:** To understand the full potential of this compound, researchers would need to:

* **Synthesize and Characterize:** The compound needs to be synthesized in a lab, purified, and its structure confirmed.
* **Biological Activity Testing:** Experiments are needed to assess its potential therapeutic properties (e.g., in vitro cell cultures, animal models).
* **Mechanism of Action:** Research would aim to understand how the compound interacts with biological systems and what cellular pathways it targets.
* **Safety and Toxicity:** Extensive studies are required to assess the compound's safety profile in order to determine its potential for human use.

**In summary, while the compound is complex and has a unique structure, its specific importance for research hinges on its potential pharmacological activity, which remains to be investigated through rigorous experimentation.**

1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone: G-1 was able to induce both c-fos expression and proliferation in the ERalpha-negative/GPR30-positive SKBR3 breast cancer cells, the requirement for ERalpha expression in GPR30/EGFR signaling may depend on the specific cellular context of different tumor types [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5322399
CHEMBL ID	569766
CHEBI ID	156296
SCHEMBL ID	12700948
MeSH ID	M0507645

Synonym
lns-8801
lns8801
gtpl1014
1-[4-(6-bromo-benzo[1,3]dioxol-5-yl)-3-alpha-4,5,9-beta-tetrahydro-3h-cyclopenta[c]quinolin-8-yl]-ethanone
ml051
UNM000011063001
UNM000000675701
1-(4-(6-bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta[c]quinolin-8-yl)-ethanone
gpr30 agonist, g-1
STK330808
1-[(3as,4r,9br)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta[c]quinolin-8-yl]ethanone
CHEBI:156296
gper agonist
CHEMBL569766 ,
cid_3136849
cid_5322399
bdbm50303803
1-((3as,4r,9br)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta[c]quinolin-8-yl)ethanone
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone
g-1 cpd
AKOS015969580
SCHEMBL12700948
(+/-)-1-[(3ar,4s,9bs*)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta[c]quinolin-8-yl]- ethanone
925419-53-0
HMS3650I22
sr-01000506928
SR-01000506928-1
unii-y3v5bv7okm
y3v5bv7okm ,
g 1 (anti-tumor agent)
EX-A3642
HY-107216
CS-0027669
HMS3678A07
Q27077759
SR-01000506928-3
HMS3414A07
ethanone, 1-((3ar,4s,9bs)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)-, rel-
g 1 (g protein-coupled estrogen receptor agonist)
g 1 (gper agonist)
ethanone, 1-((3as,4r,9br)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)-
TFS4QE36ZG ,
unii-tfs4qe36zg

Class	Description
agonist	Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Estrogen receptor	Homo sapiens (human)	Ki	10.0000	0.0000	0.4229	7.9070	AID498758; AID503066
Orexin receptor type 2	Rattus norvegicus (Norway rat)	Ki	0.0110	0.0001	0.0055	0.0110	AID769552
G-protein coupled estrogen receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0110	0.0110	0.0110	AID443558
G-protein coupled estrogen receptor 1	Homo sapiens (human)	Ki	0.0097	0.0070	0.0097	0.0110	AID498757; AID503065; AID769552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
estrogen receptor alpha, partial	Homo sapiens (human)	EC50 (µMol)	0.0487	0.0366	0.0366	0.0366	AID1223
GPER protein	Homo sapiens (human)	EC50 (µMol)	0.0111	0.0111	0.0111	0.0111	AID1224
Orexin receptor type 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0020	0.0020	0.0020	0.0020	AID769553
Estrogen receptor beta	Homo sapiens (human)	EC50 (µMol)	0.1838	0.0000	0.4795	4.8900	AID1221
G-protein coupled estrogen receptor 1	Homo sapiens (human)	EC50 (µMol)	0.4847	0.0020	0.4847	1.4500	AID1387592; AID503076; AID769553
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
antral ovarian follicle growth	Estrogen receptor	Homo sapiens (human)
epithelial cell development	Estrogen receptor	Homo sapiens (human)
chromatin remodeling	Estrogen receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
signal transduction	Estrogen receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Estrogen receptor	Homo sapiens (human)
androgen metabolic process	Estrogen receptor	Homo sapiens (human)
male gonad development	Estrogen receptor	Homo sapiens (human)
negative regulation of gene expression	Estrogen receptor	Homo sapiens (human)
positive regulation of phospholipase C activity	Estrogen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
response to estradiol	Estrogen receptor	Homo sapiens (human)
regulation of toll-like receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Estrogen receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Estrogen receptor	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
response to estrogen	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
stem cell differentiation	Estrogen receptor	Homo sapiens (human)
regulation of inflammatory response	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
RNA polymerase II preinitiation complex assembly	Estrogen receptor	Homo sapiens (human)
uterus development	Estrogen receptor	Homo sapiens (human)
vagina development	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord elongation	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	Estrogen receptor	Homo sapiens (human)
regulation of branching involved in prostate gland morphogenesis	Estrogen receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Estrogen receptor	Homo sapiens (human)
mammary gland alveolus development	Estrogen receptor	Homo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongation	Estrogen receptor	Homo sapiens (human)
protein localization to chromatin	Estrogen receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of miRNA transcription	Estrogen receptor	Homo sapiens (human)
regulation of epithelial cell apoptotic process	Estrogen receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor beta	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor beta	Homo sapiens (human)
signal transduction	Estrogen receptor beta	Homo sapiens (human)
cell-cell signaling	Estrogen receptor beta	Homo sapiens (human)
negative regulation of cell growth	Estrogen receptor beta	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor beta	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor beta	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor beta	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor beta	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor beta	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor beta	Homo sapiens (human)
vasodilation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of protein phosphorylation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of neurotransmitter secretion	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of leukocyte activation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
inflammatory response	G-protein coupled estrogen receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nervous system development	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of cell population proliferation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of cell population proliferation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of gene expression	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of gene expression	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of cell cycle process	G-protein coupled estrogen receptor 1	Homo sapiens (human)
neuronal action potential	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cell differentiation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
apoptotic chromosome condensation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nuclear fragmentation involved in apoptotic nuclear change	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of cell migration	G-protein coupled estrogen receptor 1	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of insulin secretion	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic process	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of apoptotic process	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	G-protein coupled estrogen receptor 1	Homo sapiens (human)
steroid hormone mediated signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of MAPK cascade	G-protein coupled estrogen receptor 1	Homo sapiens (human)
innate immune response	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of fat cell differentiation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of inflammatory response	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of neurogenesis	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of lipid biosynthetic process	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	G-protein coupled estrogen receptor 1	Homo sapiens (human)
regulation of cytosolic calcium ion concentration	G-protein coupled estrogen receptor 1	Homo sapiens (human)
regulation of cell cycle	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cellular response to glucose stimulus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cellular response to tumor necrosis factor	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cellular response to peptide hormone stimulus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cellular response to mineralocorticoid stimulus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cellular response to estradiol stimulus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of endothelial cell apoptotic process	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of cardiac vascular smooth muscle cell differentiation	G-protein coupled estrogen receptor 1	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	G-protein coupled estrogen receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
TFIIB-class transcription factor binding	Estrogen receptor	Homo sapiens (human)
transcription coregulator binding	Estrogen receptor	Homo sapiens (human)
transcription corepressor binding	Estrogen receptor	Homo sapiens (human)
transcription coactivator binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
chromatin binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor	Homo sapiens (human)
steroid binding	Estrogen receptor	Homo sapiens (human)
protein binding	Estrogen receptor	Homo sapiens (human)
calmodulin binding	Estrogen receptor	Homo sapiens (human)
beta-catenin binding	Estrogen receptor	Homo sapiens (human)
zinc ion binding	Estrogen receptor	Homo sapiens (human)
TBP-class protein binding	Estrogen receptor	Homo sapiens (human)
enzyme binding	Estrogen receptor	Homo sapiens (human)
protein kinase binding	Estrogen receptor	Homo sapiens (human)
nitric-oxide synthase regulator activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor binding	Estrogen receptor	Homo sapiens (human)
estrogen response element binding	Estrogen receptor	Homo sapiens (human)
identical protein binding	Estrogen receptor	Homo sapiens (human)
ATPase binding	Estrogen receptor	Homo sapiens (human)
14-3-3 protein binding	Estrogen receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Estrogen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor beta	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor beta	Homo sapiens (human)
DNA binding	Estrogen receptor beta	Homo sapiens (human)
nuclear steroid receptor activity	Estrogen receptor beta	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor beta	Homo sapiens (human)
steroid binding	Estrogen receptor beta	Homo sapiens (human)
protein binding	Estrogen receptor beta	Homo sapiens (human)
zinc ion binding	Estrogen receptor beta	Homo sapiens (human)
enzyme binding	Estrogen receptor beta	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor beta	Homo sapiens (human)
estrogen response element binding	Estrogen receptor beta	Homo sapiens (human)
receptor antagonist activity	Estrogen receptor beta	Homo sapiens (human)
chromatin binding	G-protein coupled estrogen receptor 1	Homo sapiens (human)
G protein-coupled receptor activity	G-protein coupled estrogen receptor 1	Homo sapiens (human)
steroid binding	G-protein coupled estrogen receptor 1	Homo sapiens (human)
protein binding	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nuclear estrogen receptor activity	G-protein coupled estrogen receptor 1	Homo sapiens (human)
G protein-coupled estrogen receptor activity	G-protein coupled estrogen receptor 1	Homo sapiens (human)
steroid hormone binding	G-protein coupled estrogen receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Estrogen receptor	Homo sapiens (human)
nucleoplasm	Estrogen receptor	Homo sapiens (human)
transcription regulator complex	Estrogen receptor	Homo sapiens (human)
cytoplasm	Estrogen receptor	Homo sapiens (human)
Golgi apparatus	Estrogen receptor	Homo sapiens (human)
cytosol	Estrogen receptor	Homo sapiens (human)
plasma membrane	Estrogen receptor	Homo sapiens (human)
membrane	Estrogen receptor	Homo sapiens (human)
chromatin	Estrogen receptor	Homo sapiens (human)
euchromatin	Estrogen receptor	Homo sapiens (human)
protein-containing complex	Estrogen receptor	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nucleus	Estrogen receptor beta	Homo sapiens (human)
nucleoplasm	Estrogen receptor beta	Homo sapiens (human)
mitochondrion	Estrogen receptor beta	Homo sapiens (human)
intracellular membrane-bounded organelle	Estrogen receptor beta	Homo sapiens (human)
chromatin	Estrogen receptor beta	Homo sapiens (human)
nucleus	Estrogen receptor beta	Homo sapiens (human)
plasma membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
Golgi membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nucleus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nuclear envelope	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nucleoplasm	G-protein coupled estrogen receptor 1	Homo sapiens (human)
nucleolus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cytoplasm	G-protein coupled estrogen receptor 1	Homo sapiens (human)
early endosome	G-protein coupled estrogen receptor 1	Homo sapiens (human)
endoplasmic reticulum	G-protein coupled estrogen receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
Golgi apparatus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
trans-Golgi network	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cytosol	G-protein coupled estrogen receptor 1	Homo sapiens (human)
plasma membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
postsynaptic density	G-protein coupled estrogen receptor 1	Homo sapiens (human)
axon	G-protein coupled estrogen receptor 1	Homo sapiens (human)
dendrite	G-protein coupled estrogen receptor 1	Homo sapiens (human)
cytoplasmic vesicle membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
mitochondrial membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
dendritic spine membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
presynaptic membrane	G-protein coupled estrogen receptor 1	Homo sapiens (human)
dendritic shaft	G-protein coupled estrogen receptor 1	Homo sapiens (human)
intracellular membrane-bounded organelle	G-protein coupled estrogen receptor 1	Homo sapiens (human)
axon terminus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
dendritic spine head	G-protein coupled estrogen receptor 1	Homo sapiens (human)
keratin filament	G-protein coupled estrogen receptor 1	Homo sapiens (human)
perinuclear region of cytoplasm	G-protein coupled estrogen receptor 1	Homo sapiens (human)
presynaptic active zone	G-protein coupled estrogen receptor 1	Homo sapiens (human)
recycling endosome	G-protein coupled estrogen receptor 1	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	G-protein coupled estrogen receptor 1	Homo sapiens (human)
Golgi apparatus	G-protein coupled estrogen receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay ID	Title	Year	Journal	Article
AID446626	Antagonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as inhibition of estradiol-induced PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID446624	Antagonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as inhibition of estradiol-induced PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID498757	Binding affinity to GPR30 in human Hec50 cells by competitive binding assay	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	In vivo effects of a GPR30 antagonist.
AID503166	Inhibition of chemoattractant-induced cell migration of human SK-BR-3 cells after 48 hrs by transwell migration assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID769553	Agonist activity at GPR30 (unknown origin) by calcium mobilization assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID503072	Agonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as increase in intracellular calcium level at 1 nM by spectrofluorimetry	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503161	Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as PI3K activation at 10 nM by PIP3 nuclear accumulation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID1387595	Cytotoxicity against human SKBR3 cells assessed as decrease in cell viability at 1 uM after 72 hrs in presence of GPER agonist E2 by MTS assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387597	Displacement of fluoromone from recombinant human full length untagged estrogen receptor beta expressed in insect cells after 2 hrs by fluorescence polarization assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID498758	Binding affinity to ERalpha receptor in COS7 cells by competitive binding assay	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	In vivo effects of a GPR30 antagonist.
AID503159	Agonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as PI3K activation at 10 nM by PIP3 nuclear accumulation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503164	Agonist activity at GPR30 in human SK-BR-3 cells endogenously expressing only GPR30 assessed as PI3K activation at 10 nM by PIP3 nuclear accumulation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503165	Agonist activity at GPR30 in human MCF7 cells endogenously expressing both GPR30 and ER assessed as PI3K activation at 10 nM by PIP3 nuclear accumulation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503068	Displacement of E2-Alexa633 from GFP-tagged ERalpha expressed in COS7 cells at 1 uM by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503162	Binding affinity to mRFP1-tagged GPR30 expressed in COS7 cells coexpressing GFP-tagged ERalpha assessed as inhibition of E2-Alexa633 binding in nucleus at 1 uM by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503069	Displacement of E2-Alexa633 from GFP-tagged ERbeta expressed in COS7 cells at 1 uM by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID443558	Binding affinity to GPR30	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID1387605	Cytotoxicity against human SKBR3 cells assessed as decrease in cell viability at 1 uM after 72 hrs in absence of GPER agonist E2 by MTS assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387596	Displacement of fluoromone from recombinant human full length untagged estrogen receptor alpha expressed in insect cells after 2 hrs by fluorescence polarization assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387601	Agonist activity at GPER (unknown origin) expressed in human HL60 cells assessed as increase in cAMP accumulation at 1 uM after 20 mins by HTRF assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID446625	Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay relative to 10 nM estradiol	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID1387608	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability at 1 uM after 72 hrs in presence of GPER agonist E2 by MTS assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID769552	Inhibition of estrogen binding to GPR30 (unknown origin)	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID503073	Agonist activity at GFP-tagged ERbeta expressed in COS7 cells assessed as increase in intracellular calcium level at 1 nM by spectrofluorimetry	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503065	Displacement of E2-Alexa633 from GFP-tagged GPR30 expressed in COS7 cells by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID446619	Displacement of estradiol-Alexa 633 from GFP-tagged ERbeta expressed in COS7 cells at 10 uM	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID446623	Agonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay relative to 10 nM estradiol	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID446618	Displacement of estradiol-Alexa 633 from GFP-tagged ERalpha expressed in COS7 cells at 10 uM	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID503070	Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as half life for increase in intracellular calcium level at 1 nM by spectrofluorimetry	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID446621	Agonist activity at GPR30 in human SKBr3 cells assessed as stimulation of calcium mobilization at 10 uM relative to 200 nM estradiol	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID503076	Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as half life for increase in intracellular calcium level by spectrofluorimetry	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503163	Binding affinity to GFP-tagged ERalpha expressed in COS7 cells coexpressing mRFP1-tagged GPR30 assessed as inhibition of E2-Alexa633 binding in nucleus at 1 uM by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503167	Inhibition of chemoattractant-induced cell migration of human MCF7 cells after 48 hrs by transwell migration assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID503160	Agonist activity at GFP-tagged ERbeta expressed in COS7 cells assessed as PI3K activation at 10 nM by PIP3 nuclear accumulation assay	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID446622	Antagonist activity at GPR30 in human SKBr3 cells assessed as inhibition of estradiol-induced calcium mobilization at 10 uM	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID503064	Displacement of E2-Alexa633 from GFP-tagged GPR30 expressed in COS7 cells at 10 uM by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID1387602	Agonist activity at GPER (unknown origin) expressed in human HL60 cells assessed as increase in cAMP accumulation at 1 uM incubated for 20 mins followed by GPER antagonist G15 addition measured after 10 mins by HTRF assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID498771	Effect on uterine weight in ovariectomized C57B16 mouse at 0.1 to 2.4 nM, sc	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	In vivo effects of a GPR30 antagonist.
AID503066	Displacement of E2-Alexa633 from GFP-tagged ERalpha expressed in COS7 cells by FACS	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID498764	Stimulation of GPR30-mediated epithelial uterine cell proliferation in ovariectomized C57B16 mouse at 0.1 to 2.4 nM, sc relative to control	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	In vivo effects of a GPR30 antagonist.
AID1387600	Agonist activity at GPER (unknown origin) expressed in human HL60 cells assessed as increase in cAMP accumulation at 10 uM after 20 mins by HTRF assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387594	Decrease in cAMP accumulation in human HL60 cells harboring GPER siRNA at 100 nM after 48 hrs by HTRF assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387606	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability at 1 uM after 72 hrs in presence of GPER agonist E2 by MTS assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387607	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability at 1 uM after 72 hrs in absence of GPER agonist E2 by MTS assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID1387592	Agonist activity at GPER (unknown origin) expressed in human HL60 cells assessed as increase in cAMP accumulation in presence of IBMX after 15 mins by HTRF assay	2018	ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9	A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.
AID446620	Displacement of 1-{2-[4-(6-bromobenzo[1,3]dioxol-5- yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethyl}- 3-(3-iodo(125)-phenyl)urea from GPR30 in human Hec50 cells	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.
AID1345880	Human GPER (G protein-coupled estrogen receptor)	2006	Nature chemical biology, Apr, Volume: 2, Issue:4	Virtual and biomolecular screening converge on a selective agonist for GPR30.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (9.92)	29.6817
2010's	106 (80.92)	24.3611
2020's	12 (9.16)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (1.52%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	130 (98.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dimetridazole Dimetridazole: A compound used to treat histomoniasis in poultry.. dimetridazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by methyl groups. An antiprotozoal drug, it has been banned by both the Government of Canada and the European Union as a livestock feed additive owing to suspicions of it being carcinogenic.	2.1	1	C-nitro compound; imidazoles	antiparasitic agent; antiprotozoal drug
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.53	2	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.48	2	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.78	3	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
temozolomide [no description available]	2.31	1	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
urethane [no description available]	2.11	1	carbamate ester	fungal metabolite; mutagen
corticosterone [no description available]	2.1	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
aldosterone [no description available]	2.31	1	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	2.13	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.13	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	2.13	1	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	2.08	1	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
bisphenol a 4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro. bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom.. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.	2.13	1	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.13	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.11	1	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.17	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	7.35	126	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.15	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.21	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
etoposide [no description available]	2.11	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.1	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol [no description available]	2.03	1	stilbenoid
alfatradiol alfatradiol: used for treating androgenetic alopecia. 17alpha-estradiol : An estradiol that is estra-1,3,5(10)-triene substituted by hydroxy groups at positions 3 and 17 (the 17alpha stereoisomer).	2.03	1	17alpha-hydroxy steroid; 3-hydroxy steroid; estradiol	estrogen; geroprotector
1,2,3,4-tetrahydroquinoline 1,2,3,4-tetrahydroquinoline: structure in first source. 1,2,3,4-tetrahydroquinoline : A member of the class of quinolines that is the 1,2,3,4-tetrahydro derivative of quinoline.	2.05	1	quinolines
4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene: bisphenol A metabolite; structure in first source	2.31	1	phenols
8-((4-chlorophenyl)thio)cyclic-3',5'-amp 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP: lowers cAMP in heart & fat cells; cAMP-dependent kinase inhibitor. 8-(4-chlorophenylthio)-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a 4-chlorophenylthio group.	2.15	1	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; aryl sulfide; organochlorine compound	protein kinase agonist
2,3-bis(4-hydroxyphenyl)-propionitrile 2,3-bis(4-hydroxyphenyl)-propionitrile: a selective estrogen receptor beta agonist or modulator. also called DPN compound. 2,3-bis(4-hydroxyphenyl)propionitrile : A nitrile that is acetonitrile in which one of the hydrogens is replaced by a 4-hydroxyphenyl group while a second hydrogen is replaced by a 4-hydroxybenzyl group. It is a specific agonist for estrogen receptor beta (ERbeta).	2.8	3	nitrile; phenols	estrogen receptor agonist
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.57	8	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
n(g)-iminoethylornithine [no description available]	2.08	1	L-alpha-amino acid
angiotensin ii, des-phe(8)- Ile(5)-angiotensin II (1-7) : An angiotensin compound consisting of the linear heptapeptide sequence L-Asp-L-Arg-L-Val-L-Tyr-L-Ile-L-His-L-Pro.	2.31	1	amino acid zwitterion; angiotensin	vasodilator agent
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	3.35	6	amino acid zwitterion; angiotensin II	human metabolite
estradiol 3-benzoate 17beta-estradiol 3-benzoate : A benzoate ester resulting from the formal condensation of benzoic acid with the phenolic hydroxy group of 17beta-estradiol.	2.1	1	17beta-hydroxy steroid; benzoate ester	estrogen receptor agonist; xenoestrogen
wortmannin [no description available]	2.05	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
bradykinin [no description available]	2.15	1	oligopeptide	human blood serum metabolite; vasodilator agent
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	2.25	1	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.06	1	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	2.05	1	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.13	1	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.	2.07	1	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
tamoxifen [no description available]	3.34	6	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
nadp [no description available]	2.05	1
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole: an amyloid imaging agent; structure in first source	3.18	1
sirtinol [no description available]	2.11	1	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.13	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
rtki cpd RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors	2.17	1
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	2.1	1
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.25	1
jhw 015 [no description available]	3.18	1	indolecarboxamide
genistein [no description available]	2.13	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.07	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone WIN 55212-2 : A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group.	3.18	1	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.13	1	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.31	1	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
am 1241 AM 1241: a CB(2) receptor-selective agonist; no further information available 11/2001	3.18	1
atrial natriuretic factor Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.	2.07	1	polypeptide
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	2.52	2
sapogenins Sapogenins: The aglucon moiety of a saponin molecule. It may be triterpenoid or steroid, usually spirostan, in nature.	2.1	1
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2.08	1
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	2.48	2	polypeptide
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.06	1
angiotensin i Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.	2.31	1	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent

Condition	Relationship Strength	Studies
Cancer of Endometrium [description not available]	2.47	2
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.47	2
Breast Cancer [description not available]	4.19	15
Breast Neoplasms Tumors or cancer of the human BREAST.	4.19	15
Astrocytoma, Grade IV [description not available]	2.31	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.31	1
Allergic Rhinitis [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4	12
Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS.	2.25	1
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	2.52	2
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.52	2
Blood Pressure, High [description not available]	3.62	8
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	3.62	8
Cancer of Ovary [description not available]	3.01	4
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.01	4
Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES.	2.31	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.31	1
Colorectal Cancer [description not available]	2.15	1
Hormone-Dependent Neoplasms [description not available]	2.15	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.15	1
Malignant Melanoma [description not available]	2.15	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.15	1
Affective Disorders [description not available]	2.21	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.53	2
Mood Disorders Those disorders that have a disturbance in mood as their predominant feature.	2.21	1
Disease Exacerbation [description not available]	2.86	3
Bone Cancer [description not available]	2.21	1
Metastase [description not available]	2.54	2
Osteogenic Sarcoma [description not available]	2.21	1
Invasiveness, Neoplasm [description not available]	2.88	3
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.21	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.54	2
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.21	1
Cancer of Stomach [description not available]	2.21	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.21	1
Left Ventricular Dysfunction [description not available]	2.52	2
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	2.52	2
Allergic Encephalomyelitis [description not available]	2.75	3
Interstitial Cell Tumor [description not available]	2.08	1
Cancer of Testis [description not available]	2.08	1
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	2.08	1
Adenocarcinoma, Basal Cell [description not available]	2.5	2
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.5	2
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.08	1
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.78	3
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.1	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.52	2
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.52	2
Infections, Trichomonas [description not available]	2.1	1
Trichomonas Infections Infections in birds and mammals produced by various species of Trichomonas.	2.1	1
Cardiac Remodeling, Ventricular [description not available]	2.49	2
Cardiovascular Stroke [description not available]	2.47	2
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.47	2
Androgen-Independent Prostatic Cancer [description not available]	2.1	1
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	2.1	1
Atherogenesis [description not available]	2.1	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.1	1
Endometrioma An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.	2.52	2
Corpus Luteum Cyst [description not available]	2.52	2
Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	2.52	2
Ovarian Cysts General term for CYSTS and cystic diseases of the OVARY.	2.52	2
Carcinoma, Non-Small Cell Lung [description not available]	2.11	1
Cancer of Lung [description not available]	2.11	1
Lymph Node Metastasis [description not available]	2.11	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.11	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.11	1
Cancer of Cervix [description not available]	2.11	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.11	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.11	1
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	3.03	1
Injury, Myocardial Reperfusion [description not available]	2.76	3
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.48	2
Adrenocortical Carcinoma A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.	2.11	1
Adrenal Cortex Cancer [description not available]	2.11	1
Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX.	2.11	1
Aura [description not available]	2.13	1
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	2.13	1
Hepatocellular Carcinoma [description not available]	2.13	1
Cancer of Liver [description not available]	2.13	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.13	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.13	1
Pulmonary Arterial Remodeling [description not available]	2.13	1
Injuries, Spinal Cord [description not available]	2.5	2
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	2.5	2
Angiogenesis, Pathologic [description not available]	2.15	1
Visceral Pain Pain originating from internal organs (VISCERA) associated with autonomic phenomena (PALLOR; SWEATING; NAUSEA; and VOMITING). It often becomes a REFERRED PAIN.	2.15	1
MS (Multiple Sclerosis) [description not available]	2.05	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.05	1
Cancer of Prostate [description not available]	2.05	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.05	1
Ache [description not available]	2.06	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.06	1
Diabetes Mellitus, Adult-Onset [description not available]	2.06	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.06	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.06	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.06	1
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.06	1
Abnormalities, Multiple Congenital abnormalities that affect more than one organ or body structure.	2.07	1
Left Ventricular Hypertrophy [description not available]	2.07	1
Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.	2.07	1
Nociceptive Pain Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.	2.07	1
Fibroid [description not available]	2.08	1
Cancer of the Uterus [description not available]	2.08	1
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	2.08	1
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.08	1
Bradyarrhythmia [description not available]	2.08	1
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	2.08	1
Cardiac Failure [description not available]	2.07	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.07	1
Innate Inflammatory Response [description not available]	2.07	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.07	1
Injury, Ischemia-Reperfusion [description not available]	2.08	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.08	1
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	2.04	1
Allodynia [description not available]	2.04	1

1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone

Description

Cross-References

Synonyms (43)

Research Excerpts

Drug Classes (1)

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (92)

Molecular Functions (32)

Ceullar Components (35)

Bioassays (47)

Research

Studies (131)

Market Indicators

Research Demand Index: 10.26

Study Types

1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone

Description

Cross-References

Synonyms (43)

Research Excerpts

Drug Classes (1)

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (92)

Molecular Functions (32)

Ceullar Components (35)

Bioassays (47)

Research

Studies (131)

Market Indicators

Research Demand Index: 10.26

Study Types

Related Drugs (61)

Related Conditions (115)